tiprankstipranks
Trending News
More News >
Avacta Group plc (GB:AVCT)
:AVCT
UK Market
Advertisement

Avacta Group plc (AVCT) Earnings Dates, Call Summary & Reports

Compare
66 Followers

Earnings Data

Report Date
Apr 16, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
Last Year’s EPS
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Sep 30, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in its clinical programs and preclinical data, with strategic collaborations enhancing market potential. However, financial constraints and the absence of secured partnerships pose challenges. Shareholder concerns regarding the share price remain unaddressed.
Company Guidance
During the Avacta Group plc Interim Results Investor Presentation, several key metrics were discussed regarding the company's clinical programs and financial status. The call highlighted Avacta's progress in its clinical stage programs, notably faridoxorubicin (FAP-Dox or AVA6000) and FAP-exatecan, with the former advancing to Phase Ib and the latter on track for its first patient dosing in Q1 2026. The company presented encouraging preliminary data for faridoxorubicin in salivary gland cancers and outlined plans for further data updates at ESMO 2025. Financially, Avacta reported cash and cash equivalents of GBP 12.65 million as of June 30, 2025, with cash outflows from operations at GBP 12.14 million for the first half of 2025. The management highlighted a renegotiation of the Heights Convertible Bond and a GBP 6.5 million gross fundraising to support quarterly bond payments. Additionally, Avacta anticipates releasing further data on its programs, including a pipeline update leveraging its pre|CISION platform, with an emphasis on strategic partnerships and business development to support its financial strategy and minimize shareholder dilution.
Clinical Program Progress
Avacta's lead program, faridoxorubicin (FAP-Dox or AVA6000), is advancing with promising preliminary data in salivary gland cancers. The company also anticipates dosing the first patient with FAP-exatecan in Q1 2026.
Encouraging Preclinical Data
Updated preclinical data for FAP-exatecan shows durable complete responses in animal models, indicating potential efficacy and durability of the response.
Financial Management
Avacta maintains a cash runway into Q1 2026. Recent financial activities include renegotiation of the Heights Convertible Bond and raising GBP 6.5 million to fund bond payments.
Strategic Collaborations
The Tempus collaboration has confirmed the market opportunity for Avacta's pre|CISION medicines, showing FAP expression in 90% of patients with solid tumors.

Avacta Group plc (GB:AVCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GB:AVCT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 16, 2026
2025 (Q4)
- / -
Sep 30, 2025
2025 (Q2)
- / -0.04
-0.038-10.53% (>-0.01)
Jun 06, 2025
2024 (Q4)
- / -
-0.049
Sep 30, 2024
2024 (Q2)
- / -0.04
-0.04311.63% (<+0.01)
Apr 30, 2024
2023 (Q4)
- / -0.05
-0.11657.76% (+0.07)
Sep 28, 2023
2023 (Q2)
- / -0.04
-0.036-19.44% (>-0.01)
Apr 25, 2023
2022 (Q4)
-0.05 / -0.12
-0.064-81.25% (-0.05)
Sep 29, 2022
2022 (Q2)
- / -0.04
-0.04112.20% (<+0.01)
Apr 06, 2022
2021 (Q4)
- / -0.06
-0.048-33.33% (-0.02)
Sep 30, 2021
2021 (Q2)
- / -0.04
-0.037-10.81% (>-0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:AVCT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Sep 30, 2025
51.00p59.50p+16.67%
Jun 06, 2025
34.25p32.50p-5.11%
Sep 30, 2024
51.50p49.00p-4.85%
Apr 30, 2024
48.30p45.75p-5.28%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Avacta Group plc (GB:AVCT) report earnings?
Avacta Group plc (GB:AVCT) is schdueled to report earning on Apr 16, 2026, Before Open (Confirmed).
    What is Avacta Group plc (GB:AVCT) earnings time?
    Avacta Group plc (GB:AVCT) earnings time is at Apr 16, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Avacta Group plc stock?
          The P/E ratio of Avacta Group plc is N/A.
            What is GB:AVCT EPS forecast?
            Currently, no data Available
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis